Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Screener® version 14. As the leading platform for all in-vitro screening, the newest version of Genedata Screener further accelerates analysis of assays with more automation and guided workflow support. Version 14 deepens compound qualification from biological assays by providing compound-centric overviews and results across experiments, sub-experiments, assay groups, and panels. This new version also brings to market new capabilities for collaborative pharmaceutical research.
Screening Platform of Choice for More than 50% of the World’s Top 25 Pharmaceutical Research Firms
Global adoption of Genedata Screener continues to increase rapidly. Today, more than half of the world’s leading pharmaceutical companies plus some of the world’s most innovative research institutions use Genedata Screener to analyze, visualize, and manage screening data from in-vitro screening assay technologies. Providing a single platform for all screening processes across an enterprise, version 14’s enhanced automation and workflow support makes it easier than ever for all types of users – from beginners to experts – to quickly capitalize on data generated by screening experiments. Genedata Screener 14 further raises the efficiency of complex screening processes by:
The platform provides a new level of early-stage compound qualification for improved decision-making in discovery projects. Researchers are now able to collate per compound all assay results and manually or automatically qualify the compound (i.e. toxicity, mechanism-of-action) with a side-by-side comparison of alternate analysis models and visualizations.
Heightened Support for Collaboration Among Pharmas and CROs
Automation and standardization, which drive enterprise-wide collaboration, have long been hallmarks of the Genedata Screener platform. Screener 14 extends these capabilities to a pharmaceutical company’s external partners such as contract research organizations (CROs). It enables different levels of exchange, including:
“Genedata Screener is the platform of choice for leading pharmaceutical companies worldwide because they believe it is the best product on the market, which provides the greatest return on their investment,” said Dr. Othmar Pfannes, CEO of Genedata. “With the latest version, we now enable our customers to extend the product’s value to their partners. We do, of course, remain committed to further product development in close collaboration with our own partners to support evolving new technologies and innovative research processes. Through our collaborations, Genedata Screener will continue to be the platform of choice for all screening applications.”
New features in Genedata Screener 14 will be showcased at the following events:
- What’s New in Genedata Screener 14.0 Webinar: Oct 5, 2016 at 9:00am – 9:45am EDT; 1:00pm – 1:45pm EDT
- ELRIG Drug Discovery 2016: Oct 13 – 14, 2016 – Liverpool, UK. Booth #B3.
Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning platforms, combined with deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All product and service names mentioned are the trademarks of their respective companies.